ATP Investigators Undertake Comprehensive Brain Tissue Analysis
The Autism Tissue Program (ATP) Tissue Advisory Board recently approved five exciting new projects, marking the most comprehensive study of brain tissue in autism research to date. These studies highlight the use of donated brain tissue to explore new and provocative hypotheses about the causes of autism and shape thinking about treatment strategies.
The international Autism Genome Project Consortium (AGP) proposes to perform genome-wide genotyping and copy number variation (CNV) analysis.
The study will be carried out using ATP supplied tissue. This project is aimed at generating a resource of information for other tissue users. The AGP has already characterized 1,100 subject families with multiple autistic family members to identify and then remove those genetic samples with copy number variation, allowing improved genetic study of the remaining areas of DNA which predispose to autism.
The benefits of this study will be to discover new genetic variants associated with ASD (including genes, mutations, rearrangements and CNVs), create novel diagnostic tests for individuals and families, identify new biochemical or developmental pathways, and potential stratification of families as high and low genetic risk.
Role of MET-kinase and CASPR2 in Autism
PI: Andrew West, University of Alabama at Birmingham
Recent molecular genetics data spotlight two candidate genes, MET-kinase and CASPR2, as containing potential genetic variation associated with autism susceptibility. Using recently developed and highly specific antibodies capable of assessing the function of MET-kinase and CASPR2, coupled with new techniques to amplify partially degraded nucleic acid from brain samples, this project will help determine whether MET-kinase, CASPR2 or related protein products may serve as pathologic diagnostic indicators of ASD, and help to solidify the role of these proteins in autism susceptibility.
New pathways for targeted therapeutic intervention arise with such identification. A second goal of this proposal is to complete a genotype of each sample and deposit the data into public databases that will add to the information from the Genome Project Initiative.
Serotonin Neurons in Postmortem Autism Brains
PI: Efrain Azmitia, Professor, New York University
This study tests the hypothesis that interruption or disorder of certain serotonin fibers in the brain are an early indicator of regional abnormality or pathology.
The association of serotonin with autism is based on drug response, genetic association with serotonin-transporter gene mutations, peripheral blood levels and animal models. Still, little is known about serotonin in postmortem brains.
The goals of the project are to study the serotonergic brain cells by visualizing them using a specific serotonin transporter protein antibody. Various characteristics of these specific brain cells, including shape, fiber organization, and density of connections will be recorded and statistically compared to non-autistic brain tissue. Understanding the exact alterations of serotonin fibers will help in better understanding of the disorder and, consequently, facilitate the development of effective treatment strategies.
Comparative Analysis of Cerebellar Neuropathology in Human Autistic Patients and Cerebellar Mutant Mice
PI: Margaret Bauman, Boston University School of Medicine
Neuroanatomical and neuroimaging studies conducted by different research groups on brains of autistic subjects show faulty brain development. Amongst all brain regions affected by autism, the cerebellum is a particularly interesting research target. In contrast to the forebrain, its structure is highly conserved in mammalian evolution, and its development takes place mainly during late pregnancy and early postnatal life (a period believed to be of critical significance in autism).
A common anatomical finding is a reduced number of Purkinje cells in the cerebellum of autistic subjects. The Purkinje cell is a type of brain cell with a wide influence on many motor and non-motor regions of the brain and spinal cord. In essence, all aspects of behavior are influenced by this particular type of neuron. Importantly, the reduced numbers of Purkinje cells in autism has been traced back to the prenatal period. Purkinje cells are known to be sensitive to sex hormones (gonadal steroids), particularly estrogens, which promote their development and survival.
Also, Purkinje cells themselves are known to synthesize neurosteroids (steroid hormones produced within the brain). Preliminary data strongly suggest that Reelin, an autism candidate gene, interacts with estrogens during mouse cerebellar development. In male mice, a deficit of Reelin leads to reduced numbers of Purkinje cells, while in female mice, Purkinje cells may be protected from the Reelin deficit by high estrogen concentrations.
This phenomenon may explain, in part, the higher male prevalence of autism. The team seeks to find supporting evidence of an interaction between gonadal steroids and development of the autistic cerebellum in humans.
Metabolomics of Human Embryonic Stem Cells and Neural Precursors: A Humanized Model to Discover Biomarkers and Biochemical Pathways of Autism
PI: Gabriela Cezar, University of Wisconsin-Madison
This project addresses a critical limitation in the attempt to unravel the causes of autism: the inability to perform in utero studies of human brain cell development, and the accompanying biochemical/metabolic pathways which might give rise to autism. The work will be done by a very promising young investigator with extensive experience in the stem cell research field.
This research endeavor is essentially crossing her experience over into the proteomic (metabolomic) field of autism research. The study is exciting for several reasons. The PI has provided very strong preliminary evidence for a cellular model in which to test out most of her hypotheses (in this case measurement of kynurenine, glutamate, and GABAergic metabolites) using human embryonic stem (hES) cells that are differentiated into neural precursors and neurons.
The PI will test these expression profiles in brain tissue accrued from controls and autism subjects by previous ATP researcher Dr. Vogel, exemplifying the kind of collaboration and sharing of tissue resources that we encourage.
Autistic people have fought the inclusion of ABA in therapy for us since before Autism Speaks, and other non-Autistic-led autism organizations, started lobbying legislation to get it covered by insurances and Medicaid.
ABA is a myth originally sold to parents that it would keep their Autistic child out of an institution. Today, parents are told that with early intervention therapy their child will either be less Autistic or no longer Autistic by elementary school, and can be mainstreamed in typical education classes. ABA is very expensive to pay out of pocket. Essentially, Autism Speaks has justified the big price tag up front will offset the overall burden on resources for an Autistic’s lifetime. The recommendation for this therapy is 40 hours a week for children and toddlers.
The original study that showed the success rate of ABA to be at 50% has never been replicated. In fact, the study of ABA by United States Department of Defense was denounced as a failure. Not just once, but multiple times. Simply stated: ABA doesn’t work. In study after repeated study: ABA (conversion therapy) doesn’t work.
What more recent studies do show: Autistics who experienced ABA therapy are at high risk to develop PTSD and other lifelong trauma-related conditions. Historically, the autism organizations promoting ABA as a cure or solution have silenced Autistic advocates’ opposition. ABA is also known as gay conversion therapy.
The ‘cure’ for Autistics not born yet is the prevention of birth.
The ‘cure’ is a choice to terminate a pregnancy based on ‘autism risk.’ The cure is abortion. This is the same ‘cure’ society has for Down Syndrome.
This is eugenics 2021. Instead of killing Autistics and disabled children in gas chambers or ‘mercy killings’ like in Aktion T4, it’ll happen at the doctor’s office, quietly, one Autistic baby at a time. Different approaches yes, but still eugenics and the extinction of an entire minority group of people.
Fact: You can’t cure Autistics from being Autistic.
Fact: You can’t recover an Autistic from being Autistic.
Fact: You can groom an Autistic to mask and hide their traits. Somewhat. … however, this comes at the expense of the Autistic child, promotes Autistic Burnout (this should not be confused with typical burnout, Autistic Burnout can kill Autistics), and places the Autistic child at high risk for PTSD and other lifelong trauma-related conditions.
[Note: Autism is NOT a disease, but a neurodevelopmental difference and disability.]
Fact: Vaccines Do Not Cause Autism.